PT1140044E - Inibidores de pde 5 cgmp para inalacao no tratamento de disfuncao sexual - Google Patents

Inibidores de pde 5 cgmp para inalacao no tratamento de disfuncao sexual

Info

Publication number
PT1140044E
PT1140044E PT99964644T PT99964644T PT1140044E PT 1140044 E PT1140044 E PT 1140044E PT 99964644 T PT99964644 T PT 99964644T PT 99964644 T PT99964644 T PT 99964644T PT 1140044 E PT1140044 E PT 1140044E
Authority
PT
Portugal
Prior art keywords
inhalation
treatment
sexual dysfunction
cgmp
pde
Prior art date
Application number
PT99964644T
Other languages
English (en)
Inventor
Reto Naef
Original Assignee
Novartis Ag
Novartis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag, Novartis Pharma Gmbh filed Critical Novartis Ag
Publication of PT1140044E publication Critical patent/PT1140044E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Dispersion Chemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT99964644T 1998-12-22 1999-12-21 Inibidores de pde 5 cgmp para inalacao no tratamento de disfuncao sexual PT1140044E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9828340.1A GB9828340D0 (en) 1998-12-22 1998-12-22 Organic compounds

Publications (1)

Publication Number Publication Date
PT1140044E true PT1140044E (pt) 2006-07-31

Family

ID=10844812

Family Applications (1)

Application Number Title Priority Date Filing Date
PT99964644T PT1140044E (pt) 1998-12-22 1999-12-21 Inibidores de pde 5 cgmp para inalacao no tratamento de disfuncao sexual

Country Status (11)

Country Link
US (3) US20010055570A1 (pt)
EP (1) EP1140044B1 (pt)
JP (1) JP2002532542A (pt)
AT (1) ATE320247T1 (pt)
AU (1) AU3041900A (pt)
CA (1) CA2355368A1 (pt)
DE (1) DE69930416T2 (pt)
ES (1) ES2260952T3 (pt)
GB (1) GB9828340D0 (pt)
PT (1) PT1140044E (pt)
WO (1) WO2000037061A2 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI265925B (en) 1999-10-11 2006-11-11 Pfizer Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them
US7019136B2 (en) 2000-04-07 2006-03-28 Novartis, Ag 8-quinolinxanthine and 8-isoquinolinxanthine derivatives as PDE 5 inhibitors
GB0008694D0 (en) * 2000-04-07 2000-05-31 Novartis Ag Organic compounds
US6919337B2 (en) 2000-04-07 2005-07-19 Novartis, Ag 8-Quinolinxanthine and 8-isoquinolinxanthine derivatives as PDE 5 inhibitors
US7019010B2 (en) 2001-09-27 2006-03-28 Novertis Ag Combinations
CN1694689A (zh) * 2002-09-30 2005-11-09 阿库斯菲尔公司 供吸入的缓释多孔微粒
KR20080015594A (ko) * 2006-08-16 2008-02-20 주식회사종근당 포스포디에스테라제 저해제로서 유용한 퀴나졸린 유도체 및그 제조방법
MX2009003673A (es) 2006-10-04 2009-04-22 Pfizer Prod Inc Derivados de piridido[4,3-d]pirimidin-4(3h)-ona como antagonistas de los receptores de calcio.
US20110225023A1 (en) * 2010-03-09 2011-09-15 Target Brands, Inc. Prioritized Product Distribution
EP2526926A1 (de) * 2011-05-25 2012-11-28 Justus-Liebig-Universität Gießen Biokompatible Nanopolymerpartikel mit Wirkstoffen für die pulmonale Applikation

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225183A (en) * 1988-12-06 1993-07-06 Riker Laboratories, Inc. Medicinal aerosol formulations
US5294612A (en) * 1992-03-30 1994-03-15 Sterling Winthrop Inc. 6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-ones and compositions and method of use thereof
JP2657760B2 (ja) * 1992-07-15 1997-09-24 小野薬品工業株式会社 ４−アミノキナゾリン誘導体およびそれを含有する医薬品
GB9301192D0 (en) * 1993-06-09 1993-06-09 Trott Francis W Flower shaped mechanised table
GB9315017D0 (en) * 1993-07-20 1993-09-01 Glaxo Lab Sa Chemical compounds
US5728705A (en) * 1993-10-04 1998-03-17 The Trustees Of Columbia University In The City Of New York Method of inducing vasorelaxation to treat pulmonary hypertension
DE4420708A1 (de) * 1994-06-14 1995-12-21 Euro Celtique Sa Entzündungshemmende Zusammensetzung zur Inhalation
GB9423910D0 (en) * 1994-11-26 1995-01-11 Pfizer Ltd Therapeutic agents
CA2211729A1 (en) * 1995-03-10 1996-09-19 Sanofi Pharmaceuticals, Inc. 6-aryl pyrazolo[3,4-d¦pyrimidin-4-ones and compositions and methods of use thereof
WO1996036626A1 (de) * 1995-05-18 1996-11-21 Byk Gulden Lomberg Chemische Fabrik Gmbh Cyclohexyldihydrobenzofurane
ATE231501T1 (de) * 1995-05-18 2003-02-15 Altana Pharma Ag Phenyldihydrobenzofurane
DE19541264A1 (de) * 1995-11-06 1997-05-07 Bayer Ag Purin-6-on-derivate
EA001205B1 (ru) * 1996-01-31 2000-12-25 Бык Гульден Ломберг Хемише Фабрик Гмбх Новые фенантридины
ATE236156T1 (de) * 1996-05-31 2003-04-15 Mochida Pharm Co Ltd Pyridocarbazol derivate die einen cgmp-pde inhibilierenden effekt haben
DK0937075T3 (da) * 1996-11-11 2004-04-13 Altana Pharma Ag Hidtil ukendte imidazo- og oxazolopyridiner som phosphodiesteraseinhibitorer
AU5652698A (en) * 1996-11-12 1998-06-03 Byk Gulden Lomberg Chemische Fabrik Gmbh (2,3-dihydrobenzofuranyl)-thiazoles as phosphodiesterase inhibitors
BR9809508A (pt) * 1997-05-29 2000-06-20 Mochida Pharm Co Ltd Agente terapêutico para disfunção de ereção
US6087368A (en) * 1998-06-08 2000-07-11 Bristol-Myers Squibb Company Quinazolinone inhibitors of cGMP phosphodiesterase
TWI223598B (en) * 1998-06-22 2004-11-11 Pfizer Ireland Pharmaceuticals An intranasal pharmaceutical composition for the treatment of male erectile dysfunction or female sexual disorders, an intranasal delivery system or device and sildenafil mesylate
WO2000006121A1 (de) * 1998-07-24 2000-02-10 Jago Research Ag Medizinische aerosolformulierungen
ATE264861T1 (de) * 1998-09-04 2004-05-15 Ortho Mcneil Pharm Inc 5-heterozyklyl-pyrazolo(4,3-d)pyrimidin-7-one für die behandlung von männlichen erectilen dysfunktionen

Also Published As

Publication number Publication date
CA2355368A1 (en) 2000-06-29
US20010055570A1 (en) 2001-12-27
DE69930416D1 (de) 2006-05-11
ATE320247T1 (de) 2006-04-15
ES2260952T3 (es) 2006-11-01
US20040214831A1 (en) 2004-10-28
DE69930416T2 (de) 2006-11-02
EP1140044B1 (en) 2006-03-15
US20070197560A1 (en) 2007-08-23
JP2002532542A (ja) 2002-10-02
EP1140044A2 (en) 2001-10-10
GB9828340D0 (en) 1999-02-17
WO2000037061A2 (en) 2000-06-29
WO2000037061A3 (en) 2000-10-26
AU3041900A (en) 2000-07-12

Similar Documents

Publication Publication Date Title
CO5271711A1 (es) Una composicion que comprende sildenafil o 3-etil-5-[5-(4-etil-piperazina-1-sulfonil)-2-propoxi-fenil]-2-piridinh-2-ilmetil-2.6-dihidropirazolo[4,3-d]pirimidin-7-ona y gabapentina o pregabalina para el tratamiento de la neuropatia diabetica
CO5660266A2 (es) Sal de acido fosforico de un inhibidor de la dipeptidil peptidasa-iv
IS6288A (is) 5-(2-setnin-5-heterósýklýlsúlfónýlpýrid-3-ýl)díhýdrópýrazóló[4,3-d]pýrimidín-7-ón sem fosfódíesterasa latar
RU2007102847A (ru) Комбинация избирательного ингибитора обратного захвата норадреналина и ингибитора dev
WO2004021979A3 (en) PYRROLO[2, 3-d]PYRIMIDINE-4-YL AND PURIN-6-YL UREA COMPOUNDS
EP1599482A4 (en) PYRAZOLO1,5-A PYRIMIDINE DERIVATIVES
WO2002059083A3 (en) Novel compounds
ATE362474T1 (de) Pyrazolo(1,5-a)pyrimidine als hemmstoffe cyclin- abhängiger kinasen
IL122333A0 (en) Water-soluble adenosine kinase inhibitors
DK1699795T3 (da) Substituerede 8'-pyri(mi)dinyldihydrospiro[cycloalkylamin]-pyrimido[1,2-a]pyrimidin-6-onderivater
TW200516079A (en) Isethionate salt of a selective CDK4 inhibitor
ZA200802998B (en) Use of pyrazolo [1,5-a] pyrimidine derivatives for inhibiting protein kinases methods for inhibiting protein kinases
WO2000012504A3 (de) Dihydro-[1,2,3]triazolo-[4,5-d]pyrimidin-7-on
MY141144A (en) 1, 5-disubstituted-3,4-dihydro-1h-pyrimido 4,5-dipyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
ATE469903T1 (de) Zur behandlung von krebserkrankungen geeignete pyrazolopyrimidine
MY139336A (en) N-heteroaryl pyrazolopyrimidines as cyclin dependent kinase inhibitors
PT1140044E (pt) Inibidores de pde 5 cgmp para inalacao no tratamento de disfuncao sexual
MX2009004700A (es) Derivados de imidazo[1,2-b]piridazin y pirazolo[1,5-a] pirimidina y su uso como inhibidores de proteina cinasa.
RS52730B (sr) Kompozicija koja sadrži pde4 inhibitor i pde5 inhibitor
EP1383769A4 (en) PYRAZOLO 3,4-D] PYRIMIDINE-4-ONES 6-SUBSTITUTES USEFUL AS INHIBITORS OF KINASE DEPENDENT CYCLINES
WO2006033795A3 (en) Substituted pyrazolo [1, 5-a] pyrimidines for inhibiting abnormal cell growth
WO2004106339A3 (en) 4-SUBSTITUTED DERIVATIVES OF PYRAZOLO [3,4-d] PYRIMIDINE AND PYRROLO [2,3-d] PYRIMIDINE AND USES THEREOF
WO2004092171A3 (en) Triazolo[1,5-a]pyrimidines and pyrazolo[1,5-a]pyrimidines useful as a2a adenosin e receptor antagonists
ATE309246T1 (de) 1-(alkyl), 1-(heteroaryl)alkyl und 1-(aryl)alkyl)-7-(pyrimidin-4-yl)-imidazo(1,2-a pyrimidin-5(h)- one derivate
AU2002365211A1 (en) 6-substituted pyrazolo (3,4-d) pyrimidin-4-ones useful as cyclin dependent kinase inhibitors